h 256 has been researched along with angiotensinogen in 1 studies
| Studies (h 256) | Trials (h 256) | Recent Studies (post-2010) (h 256) | Studies (angiotensinogen) | Trials (angiotensinogen) | Recent Studies (post-2010) (angiotensinogen) |
|---|---|---|---|---|---|
| 5 | 0 | 1 | 3,606 | 78 | 875 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atrash, B; Blundell, TL; Cooper, JB; Foundling, SI; Hallett, A; Hemmings, A; Jones, DM; Sibanda, BL; Szelke, M; Watson, FE | 1 |
1 other study(ies) available for h 256 and angiotensinogen
| Article | Year |
|---|---|
Inhibitors of aspartic proteinases and their relevance to the design of antihypertensive agents.
Topics: Angiotensinogen; Antihypertensive Agents; Aspartic Acid Endopeptidases; Binding Sites; Endopeptidases; Humans; In Vitro Techniques; Models, Molecular; Molecular Conformation; Oligopeptides; Pepsin A; Protease Inhibitors; Renin | 1987 |